Kewaunee Scientific Corporation - Common Stock (KEQU)
37.99
-0.32 (-0.84%)
NASDAQ · Last Trade: Apr 2nd, 7:16 PM EDT

Kewaunee Scientific just reported results for the fourth quarter of 2024.
Via InvestorPlace · June 26, 2024

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.
Via Talk Markets · May 14, 2024

Kewaunee Scientific just reported results for the third quarter of 2024.
Via InvestorPlace · March 6, 2024

Although U.S. stocks closed mostly higher on Friday, there were a few notable insider trades.
Via Benzinga · December 18, 2023

Via Benzinga · December 7, 2023

Companies Reporting Before The Bell • Ollie's Bargain Outlet (NASDAQ:OLLI) is estimated to report quarterly earnings at $0.44 per share on revenue of $468.55 million.
Via Benzinga · December 6, 2023

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via Benzinga · March 6, 2024

Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings.
Via Benzinga · December 7, 2023

Tempur Sealy shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 87.
Via Investor's Business Daily · October 31, 2023

Via Benzinga · September 4, 2023

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Via Benzinga · July 1, 2022

Kewanuee Scientific Corp's (NASDAQ: KEQU) Indian subsidiary has secured a $17.3 million contract from Dangote Oil Refinery Company Limited for laboratory...
Via Benzinga · March 10, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Via Benzinga · June 30, 2022

Companies Reporting Before The Bell
• Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first quarter.
• Waterdrop (NYSE:WDH) is expected to report...
Via Benzinga · September 8, 2021

Companies Reporting Before The Bell
• Northern Technologies (NASDAQ:NTIC) is likely to report quarterly earnings at $0.13 per share on revenue of $14.10 million....
Via Benzinga · July 8, 2021